Strong order book, severe margin compression—growth hollow without profitability recovery
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Maintained 25% growth, 12–13% EBITDA guidance from Q1 FY27 call, but delivered margins (7.83% Q2, 8.16% H1) fall well short. PAT decline despite revenue surge is a red flag.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Prostarm delivered 82% revenue growth on a strong order book, but PAT collapsed 26.6% YoY due to cost inflation, freight headwinds, and low-margin BESS developer orders. Management claims margin recovery to 12–13% EBITDA by year-end, but H1 sits at 8%, operating cash flow is still negative, and working capital at 192 days. The new facilities (Jhajjar, Bakrol) offer structural upside if execution delivers, but near-term profitability recovery is unproven.
₹120 Cr
Revenue · +82.1% YoY₹6.1 Cr
Reported PAT · −26.6% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
EBITDA margins 12–13% by FY27 year-end
OVERSTATEDQ2 at 7.83%, H1 at ~8.16% (₹16 Cr / ₹196 Cr)
PAT margins 8.5–9% guidance
OVERSTATEDQ2 at 5.08%, H1 at 5.46% (₹11 Cr / ₹196 Cr)
Order book ₹1,121 Cr provides visibility
MET97 projects, 78% government (less price pressure but higher WC)
Margin compression temporary, due to costs, mix
METFreight doubled, low-margin BESS orders, facility startup cost—valid but no timeline given
Operating cash flow to turn positive by FY27-end
PartialStill negative at ~₹17 Cr (Sept end). March collections flagged but not guaranteed
Earnings quality
What changed since the last call
Margin guidance maintained but gap widened
DowngradeGuidance: 12–13% EBITDA by year-end. Q2 delivered 7.83%, H1 at ~8.2%. Gap of ~4–5 ppts suggests guidance out of reach or phased into next year.
BESS orders now 81% of book by value
NewOrder mix shifted heavily BESS developer (₹854 Cr / ₹1,121 Cr total). Developer model lower margin than EPC, but government tailwind strong (VGF scheme).
Operating cash flow still negative
DowngradeH1 FY27 target was positive. At Sept end: ~–₹17 Cr (improving from –₹49 Cr in Mar). Collections and billing traction noted but not yet breakeven.
New manufacturing facilities now live
UpgradeJhajjar (1.2 GWh BESS) and Bakrol (UPS, 3k units/day) operational. Expected to drive FY28+ margins and reduce third-party dependencies.
The Q&A
Paras Cheda (analyst, PurpleOne Vertex) pressed hard on margin compression: 7.83% Q2 vs 13–14% guidance, PAT down 27% despite revenue growth. Mgmt was defensive, blamed freight doubling, low-margin order execution, and facility startup costs. When asked for year-end margin recovery, mgmt hedged: 'moderate' to 12% by year-end, not guaranteed. Analysts held mgmt to 25% growth guidance but remained skeptical on margin timeline.
Margin compression — Paras Cheda, PurpleOne Vertex Ventures
PartialTemporary, due to cost inflation (freight almost doubled, elevated input costs), low-margin BESS developer execution, and facility startup overhead. Future billing should normalize; looking to ₹500 Cr EBITDA, >11% by year-end.
FY27 guidance — Paras Cheda, PurpleOne Vertex Ventures
Dodged12–13% EBITDA: should return; >11% minimum. PAT 8.5–9%: 'PAT growth would be there.' Cautious language; no firm commitment on year-end achievement.
Working capital and OCF — Paras Cheda, PurpleOne Vertex Ventures
PartialImproving. Collections accelerating (₹75 Cr in Oct, more by Dec). WC elevated due to inventory for Bakrol facility startup, new capex, and GST credit timing. By FY27-end, should trend positive. Conscious working capital blockage.
Jhajjar facility capacity — Dheraj Patel, Individual Investor
Answered1.2 GWh single-shift; can scale to 3 GWh/hour in 3-shift. Assembly-focused plant; cell procurement external. Lithium cells to remain imported unless backward integration, which is not planned yet.
Bakrol UPS facility — Aarav Jain, Individual Investor
Answered3,000 units/day capacity. Can generate ₹500–600 Cr revenue/year. Full-fledged plant with lithium integration. Gradual ramp toward factory-based assembly; benefits by FY28–29.
BESS order profitability — Paras Cheda, PurpleOne Vertex Ventures
PartialMargin under pressure due to lithium and DC block cost increases. Equity IRR dropped. Actively negotiating down-sell with 6–7 industry players; may close one soon. Benefits include mover revenue + margin recovery.
FY28 guidance — Paras Cheda, PurpleOne Vertex Ventures
Dodged25% growth is minimum, 'hard' target. But revenue may segment shift: some solar EPC down, BESS up if export, UPS up. EBITDA margin back to 12–13% possible, PAT 8.5–9%. Facility ramp will help.
BESS market competition — Devan Shah, Eternal Capital
PartialCommodity pressure yes, but Prostarm has local domestic content advantage (India banned solar imports, will ban battery imports). Local manufacturing and solution provider focus (not just EPC) = differentiation. But execution remains key.
Guidance
FY27 minimum 25% growth (maintained from Q1 FY27)
HighOrder book ₹1.1 Cr provides multi-quarter visibility. H1 achieved 62% growth; likely to moderate Q3–Q4 but 25% minimum should hold.
EBITDA 12–13% by FY27 year-end
LowCurrent H1 at 8.2%. Gap of ~4–5 ppts suggests either (a) heavy ramp in H2, or (b) guidance slip to next year. Mgmt hedged with 'should' language.
PAT margin 8.5–9% (from prior 9.5%)
LowH1 at 5.46%. Recovery depends on EBITDA improvement, finance costs, and tax rate. Mgmt said 'growth path' but no timeline.
No explicit capex guidance given
MediumFacilities now operational (Jhajjar, Bakrol); incremental capex likely modest. Debt will increase to support inventory and WC during ramp.
Risks the call surfaced
Margin compression
HighQ2 EBITDA margin 7.83% vs 12–13% guidance. Freight costs almost doubled, low-margin BESS orders, facility startup costs. Recovery path unclear.
Working capital stress
MediumWC cycle at 192 days (up from 185); inventory for Bakrol, receivables from government lag (₹257 Cr outstanding at H1, improved to ₹201 Cr by Oct). OCF negative at ~₹17 Cr Sept.
Order execution risk
MediumBESS developer orders (₹854 Cr / 76% of book) have thin margins due to lithium/DC cost inflation. 2–3 year project cycles; down-sell negotiations ongoing but outcomes uncertain.
Guidance credibility
Medium12–13% EBITDA guidance maintained from Q1, but H1 delivery at 8.2%. Gap of ~4–5 ppts. Mgmt hedged recovery to 'should' language, suggesting uncertainty.
Government order concentration
Low78% of order book from government customers; benefits from VGF/policy support but exposes to bidding and payment cycle risk.
Management
Score 6/10. CFO detailed on numbers but defensive on margins. CEO bullish on structural opportunities but vague on near-term recovery timeline. Limited transparency on BESS down-sell discussions and profitability trajectory. Strong order intake (₹1.1 Cr book, 23% YoY growth). But margin management poor: revenue up 82%, PAT down 27%. Facility ramp (Jhajjar, Bakrol) on track, but startup costs weighing down current quarter.
1 · Dec 2026 – Mar 2027
Collections from government (₹257 Cr outstanding → down to ₹201 Cr by Oct), ₹75 Cr collected in Oct alone
2 · FY28 (3+ years)
Jhajjar 1.2 GWh at 25–30% utilization; Bakrol 500–600 Cr revenue potential at higher margins
3 · Next FY
Facility ramp absorbs overhead, margin recovery to 8.5–9% PAT if BESS volume holds
The new facilities (Jhajjar, Bakrol) offer structural upside if execution delivers, but near-term profitability recovery is unproven.
Informational and educational content only. Not investment advice.